Supplement Documents for Financial Results Q3 FY12/21
Nov. 12, 2021
To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs
Chiome Bioscience Inc.
Agenda
１．Overview of Q3 FY12/21 "Financial results"
２．Overview of Q3 FY12/21 "Operation highlights"
Appendix.
Corporate information
Pipeline information
2 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Overview of
Q3 FY12/21 "Financial results"
Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.
3 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Profit and Loss
(JPY in millions)
Q3 FY2020 | Q3 FY2021 | Increase | ||
(decrease) | ||||
Net sales | 312 | 541 | 229 | |
Drug Discovery & | 2 | 103 | 100 | • Upfront payment of the License |
Agreement with Shanghai Henlius | ||||
Development | ||||
Biotech, Inc. for LIV-2008/2008b | ||||
Drug Discovery | 309 | 438 | 128 | • Growth in business with domestic |
Support | pharmaceutical companies | |||
COS/SGA | 1,392 | 1,392 | 0 | |
R&D Expense | 951 | 860 | (90) | • Cost of the study drug manufacturing |
in CBA-1535 program | ||||
Other costs | 441 | 532 | 90 | • Up in material costs due to increased |
business transactions | ||||
Operating Loss | (1,080) | (850) | 229 | |
Ordinary Loss | (1,087) | (843) | 244 | |
Net Loss | (1,087) | (842) | 245 | |
4 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Balance Sheet
(JPY in millions) | |||
As of | Dec. 31, | As of Sep. 30, | |
2020 | 2021 | ||
Current assets | 3,248 | 2,675 | |
（Cash on hand in banks) | 2,686 | 2,071 | |
(Other current assets) | 562 | 604 | |
Non-current assets | 246 | 274 | |
Total assets | 3,494 | 2,950 | |
Current Liabilities | 342 | 468 | |
Non-current liabilities | 41 | 53 | |
Total liabilities | 384 | 522 | |
Total net assets | 3,109 | 2,428 | |
Total liabilities and net assets | 3,494 | 2,950 | |
5 | ||
Copyright © 2021 Chiome Bioscience Inc. All Rights Reserved. | ||
This is an excerpt of the original content. To continue reading it, access the original document here.